Prediction of long‐term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE‐B score

An abundance of noninvasive scores have been associated with fibrosis and hepatocellular carcinoma (HCC) development. We aimed to compare the prognostic ability of these scores in relation to liver histology in chronic hepatitis B (CHB) patients. Liver biopsies from treatment‐naïve CHB patients at one tertiary care centre were scored by a single hepato‐pathologist. Laboratory values at liver biopsy were used to calculate the PAGE‐B, REACH‐B, GAG‐HCC, CU‐HCC and FIB‐4 scores. Any clinical event was defined as HCC development, liver failure, transplantation and mortality. HCC and mortality data were obtained from national database registries. Of 557 patients, 40 developed a clinical event within a median follow‐up of 10.1 (IQR 5.7‐15.9) years. The PAGE‐B score predicted any clinical event (C‐statistic.86, 95% CI: 0.80‐0.92), HCC development (C‐statistic .91) and reduced transplant‐free survival (C‐statistic .83) with good accuracy, also when stratified by ethnicity, antiviral therapy after biopsy or advanced fibrosis. The C‐statistics (95% CI) of the REACH‐B, GAG‐HCC, CU‐HCC and FIB‐4 scores for any event were .70 (0.59‐0.81), .82 (0.75‐0.89), .73 (0.63‐0.84) and.79 (0.69‐0.89), respectively. The PAGE‐B event risk assessment improved modestly when combined with the Ishak fibrosis stage (C‐statistic .87, 95% CI: 0.82‐0.93). The PAGE‐B score showed the best performance in assessing the likelihood of developing a clinical event among a diverse CHB population over 15 years of follow‐up. Additional liver histological characteristics did not appear to provide a clinically significant improvement.

[1]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[2]  M. Buti,et al.  PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. , 2016, Journal of hepatology.

[3]  T. Asselah,et al.  Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  B. Cho,et al.  High liver fibrosis index FIB‐4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers , 2015, Hepatology.

[5]  M. Buti,et al.  Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. , 2015, Journal of hepatology.

[6]  F. T. ten Kate,et al.  The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long‐term clinical outcome in chronic hepatitis B patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Lunan Yan,et al.  Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis‐4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta‐analysis , 2015, Hepatology.

[8]  M. Buti,et al.  Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians , 2014, Gut.

[9]  T. Asselah,et al.  Non‐invasive tests for fibrosis and liver stiffness predict 5‐year survival of patients chronically infected with hepatitis B virus , 2013, Alimentary pharmacology & therapeutics.

[10]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[11]  Ding‐Shinn Chen,et al.  Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads , 2013, Hepatology.

[12]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[13]  T. Roskams,et al.  EASL clinical practical guidelines: management of alcoholic liver disease. , 2012, Journal of hepatology.

[14]  Vincent Wai-Sun Wong,et al.  Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.

[15]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[16]  E. Schiff,et al.  Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B , 2010, Hepatology.

[17]  M. Brunetto,et al.  Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. , 2010, Gastroenterology.

[18]  V. Wong,et al.  Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Tsoi,et al.  Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma , 2008, Alimentary pharmacology & therapeutics.

[20]  J. Kim,et al.  Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[21]  J. Lefkowitch,et al.  Liver biopsy assessment in chronic hepatitis. , 2007, Archives of medical research.

[22]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[23]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[24]  F. Oberti,et al.  A novel panel of blood markers to assess the degree of liver fibrosis , 2005, Hepatology.

[25]  Paul Calès,et al.  Sources of variability in histological scoring of chronic viral hepatitis , 2005, Hepatology.

[26]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[27]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[28]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[29]  M. Pencina,et al.  Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. , 2014, Annals of Internal Medicine.

[30]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[31]  M. Yuen,et al.  Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. , 2009, Journal of hepatology.

[32]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[33]  J. Bruzzi,et al.  Liver biopsy. , 2001, The New England journal of medicine.